Long-range-acting gene activator elements were randomly isolated from the human genome by functional selection. HeLa cells were transfected with an enhancer trap, a plasmid containing an enhancerless xanthine-guanosine phosphoribosyltransferase (gpt) 
Identification of DNA elements that control the initiation of transcription is a crucial step in understanding the regulation of eucaryotic gene expression. Recent studies have uncovered a class of regulatory elements, called enhancers, in a variety of viral genomes (2, 6, 13, 15, 19) . Unlike classical promoters, enhancers can activate the transcription of linked genes in an orientation-independent fashion over distances of several kilobases (kb). If similar elements exist in eucaryotic genomes, they could play a key role in gene regulation. In fact, enhancers or enhancerlike elements have been found in several eucaryotic genes such as immunoglobulin genes (1, 9, 23) , the insulin gene (25) , histocompatibility antigen genes (10) , and the human beta interferon gene (8, 11) .
However, the general occurrence of enhancers or gene activator elements in eucaryotic genomes is not known. Numerous questions remain unanswered. How many enhancers are there in the human genome? What portion of genes in the genome require an enhancer? Are all enhancers tissue specific? Random isolation of enhancers from eucaryotic genomes would provide important information about the spectrum of cellular enhancers. Two such attempts have been made by others (7, 27) . In both studies fragmented (300 to 400 base pairs [bp] ) genomic DNA was ligated to an enhancerless viral genome (simian virus 40 [SV40] or polyomavirus) and transfected into appropriate permissive cells. An enhancerless viral DNA molecule that is ligated to a cellular enhancer would be able to replicate, and therefore enhancers should be recovered in infectious virus particles. In one of these studies (27) , a rescued virus genome contained an enhancer that had been artificially generated from the sequence of the defective virus genome itself, but no enhancers of cellular origin were recovered. Although an enhancerlike element was recovered in the other study (7) , it has not been well characterized, and its origin is not certain. Thus, the earlier attempts at functional selection of cellular enhancers have not been too successful, whereas such a selection procedure has been useful for identifying enhancers in virus genomes (5) .
In this study I have used a different approach to select enhancers from the human genome. My approach, which is based on the observation described in the accompanying paper (14) , that an enhancerless gene can be activated when it is integrated into a chromosome, uses the stable transformation of cells with an enhancer trap, a plasmid containing a selectable marker gene (xanthine-guanosine phosphoribosyltransferase [gpt] ) transcribed from the enhancer-dependent SV40 early promoter. The enhancerless gpt gene, which is transcriptionally inactive by itself, can be activated if it is integrated near an endogenous gene activator. The gene activators can be isolated from GPT+-transformants by cloning the human sequences flanking the enhancer trap. This selection procedure is more general than the previously described method and has several advantages. For example, only small (300 to 400-base-pair [bp]) enhancers can be rescued in the other procedure because of viral packaging constraint. On the other hand, there is no limit to the size of enhancers in my procedure. Furthermore, the functional selection in the previously published attempts was done in extrachromosomal viral DNA, while in my approach the selection is performed in cellular chromosomes, probably a more natural environment for expression selection. Here I report the successful isolation of strong gene activators from the human genome and the characterization of their functional properties.
MATERIALS AND METHODS Cells, plasmid, and phage. HuTu8O (ATCC HTB40), SK-N-SH (ATCC HTB11), SK-MEL-28 (ATCC HTB72) and U-373MG (ATCC HTB17) were obtained from the American Type Culture Collection. C33A (ATCC HTB31) and SiHa (ATCC HTB35) were provided by M. Pater. All cell lines were maintained in Dulbecco modified medium containing 10% fetal calf serum. Plasmids were propagated in Escherichia coli C600. Form I plasmid DNA was purified by CsCl-ethidium bromide centrifugation and used for DNA transfection. EMBL3A phage and E. coli NM538 were obtained from Dr Isolation of GPT+ cell lines transformed with the enhancer trap. The enhancer trap, pE°-gpt, was constructed by ligating the HindIII-BamHI 4-kilobase (kb) fragment containing an enhancerless SV40 early promoter from pAlocat (18) to the HindIII-BamHI 1.8-kb fragment containing a gpt coding sequence from pSV2-gpt (20) . pE°-gpt (10 jig) was transfected into 106 HeLa cells in a 10-cm petri dish by the CaPO4 precipitation method described previously (12) . At 48 h after transfection, the nonselective medium was replaced with selective medium containing mycophenolic acid (25 ,ug/ml) (20) . The cells were further incubated for 15 days, with the selective medium changed every 4 days. About 5 to 10 GPT+ colonies appeared in each dish. Each colony was picked and propagated in selective medium. About half of such colonies were established as stable GPT+ cell lines, while the other half failed to grow. A total of 51 stable GPT+ cell lines were obtained from two series of transfections.
Molecular cloning of human DNAs flanking the enhancer trap. BclI digests of genomic DNA from clones 037, 041, 039, and 064 and BamHI digests of genomic DNA from clone 023 were fractionated on agarose gels. DNA fragments of the appropriate size were recovered from the gel, purified, and ligated to BamHI-digested X EMBL3A DNA. The ligated DNA was subjected to the in vitro packaging reaction. The resulting recombinant phages were screened by plaque hybridization with a gpt-specific probe (HindIII-BamHI 1.8-kb fragment of pE°-gpt). Five recombinant phages, X023, X037, X039, X041, and X064, were isolated from cell lines 023, 037, 039, 041, and 064, respectively.
Subcloning of genomic DNA from phage in plasmids. The orientation of the subcloned human fragment with respect to the gpt gene was maintained in the plasmids. Constructions were also made with specific human sequences in a reversed orientation. These plasmids contain an R in their designations.
(i) 037. The BamHI-Pst 5.5-kb fragment was cloned in the corresponding site of pUC12 (pBPs-5.5). The Sal 13-kb fragment was cloned directly from X037 phage DNA by digestion with SalI followed by self-ligation (pSall3), because the amp gene and bacterial replication origin remained intact in X037. The PvuII 8-kb fragment was cloned in a similar way (ASaPv). For the construction of ASaPv-R, ASaPv was digested with BamHI and religated. ASaSm and AH were constructed from pSall3 by digestion with appropriate enzymes and self-ligation. For AB, the BamHI 8-kb fragment from pSall3 was cloned at the BamHI site of pUC12.
(ii) 041. The PstI 7.5-and the SaII 11-kb fragments were cloned at the corresponding site of pUC12 (pPst7.5 and pSalll, respectively).
(iii) 064. The SmaI-EcoRI 6.4-kb and Smal-EcoRI 6.0-kb fragments from 064 were cloned at the corresponding site of pUC12 (pSmE6.4 and pSmE6.0, respectively).
(iv) 023. The SmaI-BamHI 10-kb, Sst-BamHI 7.5-kb, and EcoRI-BamHI 5.6-kb fragments were cloned in pUC12 (pSmBlO, pSsB7.5, and pEB5.6, respectively). The SmaIPvuII 3.0-kb, SmaI-SstI 2.0-kb, EcoRI 1.0-kb, and EcoRI 1.8-kb fragments were cloned in pUC-gpt (pSmPv3.0, pSst2.0, pEcol.0, and pEcol.8, respectively). pUC-gpt contains a BglII-BamHI 1.8-kb fragment that includes the SV40 promoter, the gpt coding sequence, and poly(A) addition sequence (see Fig. 1 ) from pE°-gpt at the BamHI site of pUC12.
(v) 039. The Sall 10.5-kb and the SmaI-BamHI 6.0-kb fragments were cloned in pUC12 (pSallO.5 and pSmB6.0, respectively).
Stable transformation assay. Plasmid DNA (e.g., 10 ,ug of pE°-gpt; 2.5 pmol) was transfected to 5 x 105 recipient cells in a 10-cm petri dish. In one experiment, two plates were used for each plasmid. The same transfection procedure was used for various cell lines except that the time for the glycerol shock varied; 30 s for HeLa cells, 60 s for C33A, SiHa, and SK-MEL-28 cells, and 90 s for SK-N-SH, HuTu8O and U-373MG cells. The gpt selection was done as described previously (20) . After cells were incubated for 14 to 16 days in the selective medium, plates were stained with Giemsa stain and the number of GPTI colonies that consisted of more than 100 cells were counted. SK-N-SH cells seemed to be more resistant to mycophenolic acid than other cells, so it took longer for the GPT+ colonies to become visible. Therefore, in the case of SK-N-SH, the transfected cells were incubated for 3 weeks before the staining. At least two transfection experiments were done for each plasmid. The transformation frequency was expressed as the average GPTI colony number per plate of 5 x 105 recipient cells.
RESULTS
Strategy for the selection of gene activator elements. The strategy for the selection of gene activators is summarized in Fig. 1 . pE°-gpt, an enhancer trap, contains a dominant selectable marker gene (gpt) driven by the SV40 early promoter, but lacks enhancers (the SV40 enhancer is deleted). The SV40 promoter is known to be enhancer dependent; active expression of the linked gpt gene would require an enhancer. The enhancerless gpt genes that were randomly integrated into the HeLa cell genome after transfection were not expressed at a high enough level for the cells to survive under the selective condition unless the gene was integrated near an endogenous gene activator (data not shown; see Table 1 ). Therefore, it was assumed that at least some of the GPT+ cells that arose after transfection of the enhancer trap had the gpt gene activated by a cellular gene activator.
HeLa cells were chosen as recipient cells for transfection. When the enhancer trap was transfected into HeLa cells, GPT+ transformants appeared at a frequency of 9 x 10-6. This frequency is 200-fold lower than that of pSV2-gpt, a similar plasmid that contains the SV40 enhancer. Fifty-one GPTI cell clones transformed with the enhancer trap were isolated and propagated. Biochemical assays of GPT activity in each cell line ( Fig. 2A) indicated that all cells expressed the gpt gene at a high level, as high as in GPTI cells transformed wih pSV2-gpt.
Although the activation of the enhancerless gene by an endogenous enhancer would be a reason for the appearance of the GPIT+ cells, other events could also complement the lack of enhancers; for example, integration of multiple copies of the plasmids, amplification of a single integrant, or readthrough from an endogenous enhancer-independent promoter. To exclude the cell lines that arose by these alternative mechanisms, further selection was done. First, the copy number of the integrated trap was determined by hybridization (Fig. 2B ). About half of the 51 clones seemed to contain a single copy. Second, the 5' end of the GPT mRNA was examined by primer extension analysis. Of six cell lines examined (003, 007, 023, 024, 037, and 039), all showed a major species of GPT mRNA that was initiated at the native SV40 promoter region (data not shown). From these two MOL. CELL. BIOL.
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analyses, 18 GPT+ cell lines which seemed to have a single copy of the trap were chosen for subsequent restriction analysis and molecular cloning.
Cloning of human DNA flanking the enhancer trap. The restriction maps (Fig. 3 ) of the human DNA sequences flanking the enhancer trap in 11 cell lines were determined by genomic Southern blotting. As predicted by the dot hybridization, all cell lines except 064 contained a single copy of the gpt insert. The portion of the enhancer trap remaining in the transformants varied. For example, the PstI site located in the amp gene was retained in 007, 037, and 045 but deleted in others. The PvuII site located 1.5 kb upstream from the promoter was present in 039 and 023 (probably also in 051 and 079) but absent in other cell lines. However, the minimum essential part of the enhancer trap, the region between the promoter (0. Enhancer activity in the subcloned DNAs was first assayed by a stable transformation system. The plasmids were transfected into HeLa cells and their GPT+ transformation frequencies were determined. pE0-gpt and pSV2-gpt served as negative and positive controls, respectively. As indicated by the high transformation efficiency of 037pSal13 (Fig. 4A  and B) , strong enhancer activity was detected in the 13-kb region of the 037 DNA. On the other hand, the human DNA located upstream from the gpt gene did not show such a high efficiency 037pBPs5.5. Since the enhancer activity was retained in ASaSm and ASaPv but abolished in AB, this gene activator (termed GA1) must be located in the 3-kb region downstream from the gpt gene, between the BamHI site and the left-hand human DNA-enhancer trap junction. The activity of GAl was orientation independent because ASaPv-R, in which the orientation of GAl was reversed, was as effective as ASaPv in the transformation assay. AH, which contained GAl but lacked the SV40 promoter, did not show enhanced efficiency, indicating that GAl cannot function without an appropriate promoter.
A DNA fragment cloned from 041 also contained a gene activator. The enhancing activity was detected with 04lpSalll. Since the restriction map of the 8-kb region between the BclI site and the integration site was identical to that of the corresponding region in clone X037 DNA, the gene activator detected in 041 should be the same GAL. Similarly, the enhancer trap seemed to have been integrated next to a GAl-containing locus in the 064 cell line too, since the 6.4-kb region of 064, between the BclI site and the integration site, was also identical to the corresponding DNA regions in 037 and 041. However, enhancer activity was not observed with 064pSmE6.0, suggesting that GAl was deleted during fixation of the enhancer trap sequence. Cell line 064 will be discussed below.
A second gene activator (GA2) was found in the DNA cloned from 023, which was shown by the high transformation efficiency of 023pSmB10 ( Fig. 4A and C) . The location of GA2 was narrowed by further subcloning of various parts of 023pBSmlO. Whereas the enhancing activity was not detected in pSsB7.5 or pEB5.6, pSmPv3.0 and pSst2.0 contained the activity. Therefore, GA2 was located in the Sma-Sst 2.0-kb region, about 6 kb upstream from the SV40 promoter. Like GA1, GA2 seemed to function in an orientation-independent manner, since a similar level of enhancing activity was observed with pSmPv3.OR and pSst2.OR, in which the orientation of GA2 was reversed. AH, lacking the promoter, failed to show the activity of GA2, indicating that GA2 stimulates promoter-dependent transcription but does not increase nonspecific transcription that would start at cryptic promoters, such as the one found in pBR322 sequences (26) . Enhancer activity was not detected in the cloned 039 DNA.
Enhancement of the transformation efficiency by GAl and GA2 was most likely due to their ability to activate the linked gpt gene. However, it was possible that GAl or GA2 or both increased the efficiency by stimulating integration of the transfected plasmid. To confirm that GAl and GA2 actually activated expression of the gpt gene, the following experiments were done. pE0-gpt, 037pSa113, or 023pSmB10 was cotransfected into HeLa cells with pSV2-neo, which would confer G418 resistance. The transfected cells were first cultured in the presence of G418, and the resulting NEO+ transformants were pooled. The amount of the integrated gpt genes in the pooled NEO+ cells was determined by hybridization with a gpt specific probe. Expression of the nonselected gpt genes was examined by culturing the NEO+ cells in GPT selection medium (Table 1 ). The enhancer activity of GAl and GA2 was also assayed in a transient expression system. The chloramphenicol acetyltransferase (cat) gene, linked to the SV40 early promoter, was used for this study instead of the gpt gene, since the CAT assay is more sensitive than the GPT assay. Recombinant plasmids (pGA1-cat and pGA2-cat) in which GAl or GA2 was linked to the cat gene were constructed (Fig. 5) .
These cat plasmids, along with pA1o-cat (enhancerless) and pSV2-cat (containing the SV40 enhancer), were transfected into HeLa cells. The transfected cells were harvested 48 h after the transfection, and the CAT activity produced by each plasmid was assayed as described in Materials and Methods. The plasmids containing GAl and GA2 produced 60-fold and 30-fold, respectively, as much CAT activity as pA1o-cat. These results indicated that GAl and GA2 were active in the transient expression system. The magnitude of the enhancement observed in this assay was similar to that seen in the stable transformation assay.
Cell type specificities of GAl and GA2. Strong cellular enhancers such as the immunoglobulin gene enhancer are known to be cell type specific (1, 9, 23) . The cloned GAl and GA2 sequences were active in HeLa cells, which is natural in a sense because they were functionally selected in HeLa cells. I next investigated their cell type specificities. Since HeLa is a cervical carcinoma cell, two other cervical carcinoma cell lines (C33A and SiHa) and four noncervical cell lines (neuroblastoma, glioblastoma, malignant melanoma, and duodenum adenocarcinoma) were used for this study.
pE°-gpt, 037pSa113, 023pSmB10, or pSV2-gpt was transfected into these cells, and the frequency of GPT transformation was determined for each cell type (Table 2) . When the transformation frequencies of 037pSa1l3 were compared with those of pE°-gpt, GAl was active in two other cervical cell lines but its activity in C33A was weaker than that observed in HeLa cells. Surprisingly, GAl was fully active in neuroblastoma cells but inactive in glioblastoma cells, malignant melanoma cells, and duodenum adenocarcinoma cells. It appears that GAl can function in cervical cells and in some but not all neural cells. On the other hand, the specificity of GA2 seems to be more complex. When the transformation efficiencies of 023pSmB10 were compared with those of pE°-gpt, GA2 seemed to be active in SiHa but not in C33A cells. Moreover, GA2 was partially active in duodenum adenocarcinoma cells, but inactive in malignant melanoma cells, neuroblastoma cells, and glioblastoma cells. These results indicate that both GAl and GA2 have limited but limited cell type specificity. Organization of GAl and GA2 in the human genome. Three DNA fragments cloned from 037, 041, and 064 cells contained an identical region (from the BclI site to the integration site) within which GAl was located. However, heterogeneity in the EcoRI sites was noticed in the region beyond the BclI site (Fig. 3 ). This suggests that there is more than one copy of the GAl-containing sequence in the HeLa genome. This was confirmed by the Southern blotting analysis (Fig. 6) . A KpnI-BamHI 0.8-kb fragment was used as a hybridization probe. The probe detected multiple bands in HeLa DNA digested with EcoRI, BamHI, or HindIII. Since each hybridized band represented more than one copy (probably 5 to 10 copies; see Fig. 6 legend), the HeLa genome seems to have roughly 10 to 20 copies of the GAl sequence. The existence of multiple copies of the GAl sequence would explain why the enhancer trap was repeatedly found to be associated with the GAl-containing locus.
The frequency of integration of the enhancer trap near GAl was investigated by the digestion of 15 other GPT+ genomic DNAs followed by Southern blotting and hybridization to the KpnI-BamHI 0.8-kb fragment. The results indicated that the enhancer trap was integrated into one of the GAlcontaining loci in 007 cells (Fig. 3) , while it was integrated into different loci in the remaining 14 cell lines (data not shown). Therefore, the frequency of the association of the enhancer trap with the GAl locus is 4 of 18 cell lines.
Although the left side-flanking DNAs in 007, 037, 041, and 064 ( Fig. 3) contained an identical region, as described previously, the flanking DNAs of the other side were considerably different. However, the latter flanking regions in 007, 037, 041, and 064 (all or some of them) may derive from the same contiguous DNA, since it is conceivable that human DNA sequences near the integration site, as well as a part of enhancer trap, had been eliminated during the DNA integration and fixation. In contrast to GAl, Southern blotting analysis of HeLa genomic DNA with the 1.8-kb EcoRI fragment from 023 [the EcoRI fragment contained in the 023pEcol.8 in Fig. 4C ] as a probe detected a single band (BamHI 9.5-kb, HindIII 9.2-kb, and EcoRI 1.5-kb fragments; data not shown), suggesting that the GA2 sequence exists only once in the HeLa haploid genome.
DISCUSSION
This report has described the random isolation of gene activators from the human genome by functional selection. The successful cloning of gene activators confirms my previous suggestion, described in the accompanying paper, (14) , that an exogenously introduced enhancerless gene can be activated by an endogenous gene activator. Two isolated gene activators, GAl and GA2, activated the linked gpt gene in a manner similar to that for enhancers, i.e., GAl and GA2 can function over distances of at least 5 kb, even from downstream of the target gene, in an orientationindependent fashion. However, unlike other known cellular enhancers, GAl and GA2 showed a broad cell type specificity. GAl appeared to be active in cervical epithelial cells and certain neural cells, while the specificity of GA2 was too complex to be generalized (Table 2) . Differential activity of GA2 in two cervical carcinoma cell lines (HeLa and C33A) could be due to the cytopathological difference between two cell lines; while C33A is an undifferentiated carcinoma, (A) Functional maps of pA1o-cat, pSV2-cat, pGA1-cat, and pGA2-cat are shown. pGA1-cat was constructed by ligating the BamHI 5.2-kb fragment from ASaPv to the 1.8-kb BgllI-BamHI fragment from pA1o-cat (18) . The former fragment includes GA1, and the latter contains an enhancerless cat gene. pGA2-cat was constructed by inserting the SmaI-PvuII 3.0-kb fragment from 023pSmB10 into the SmaI site of pUC-cat. pUC-cat contains the 1.8-kb BamHI-BglII fragment from pA10-cat at the BamHI site of pUC12. The SV40 early promoter is indicated by open circles, while enhancers (SV40 enhancer, GAl, and GA2) are indicated by closed circles. The wavy lines in pGA1-cat and pGA2-cat denote the human DNA sequences. (B) pA10-cat (10 ,ug) or an equivalent molar amount of pGA1-cat, pGA2-cat, or pSV2-cat was transfected into HeLa cells as previously described for the stable transformation system. The cells were harvested 48 h after the transfection, and cell extracts were prepared HeLa is believed to be an epidermoid carcinoma. Also, one should consider that all the cell lines used in this study are malignant tumor cells. Certain oncogene products may function as trans-acting factors that can regulate the function of gene activators, either negatively or positively. In fact, adenovirus Ela protein is known to repress the activity of the SV40 and polyomavirus enhancers (4) . It is therefore possible that the observed cell type specificity reflects, to some extent, the malignant phenotype of the recipient cells. In any case, the cell type specificity of GAl and GA2 suggests that certain trans-acting factors that can influence the activity of these elements are present in some human cells but absent in others.
It has been suggested that some developmentally regulated genes and inducible genes may contain strong enhancers, while weaker enhancers may be associated with certain housekeeping genes (16) . GAl and GA2 seem to possess as strong an enhancer activity as that of the immunoglobulin gene enhancer, although their activity was not limited to cervical cells. If GAl and GA2 have an important role in gene regulation, then they should be associated with structural genes (most likely protein-coding genes) in the human genome. Furthermore, such genes should be actively expressed in HeLa cells, because GAl and GA2 were active in HeLa cells. I have recently investigated this possibility by hybridization of 32P-labeled cDNA made from HeLa polyadenylated RNA to the human DNAs cloned in this study. The results showed the presence of relatively abundant cDNA sequences that hybridized to the SalI 13-kb and the Sall 4-kb regions of X037 (unpublished data). The SstBamHI 4-kb region of X023 also hybridized to the cDNA. Therefore it seems that GAl and GA2 are closely linked to structural genes that are expressed in HeLa cells. It is important to identify the presumptive target genes and to study their expression in a variety of human cells. It is tempting to speculate that GAl and GA2 play a crucial role in the regulation of their target genes.
GAl seemed to exist in multiple (10 to 20) copies in the HeLa genome. This would explain why the enhancer trap was repeatedly (4 of 18 cell lines) found near GAl-containing loci. Considering the Southern blotting pattern shown in Fig.  6 , it is possible that the GAl elements are associated with a family of related genes or that the GAl-containing segments are tandemly repeated in the chromosomes. However, more recent studies indicate that GAl exists only once in the haploid genomes of other human cells and that the GAlcontaining segment in one allele had been translocated and then amplified in the HeLa cells (H. Hamada, manuscript in preparation). It appears that in 037, 041, 064, and 007 cells, the enhancer trap was integrated into one of the amplified GAl-containing segments.
The integration site of the enhancer trap found in 064 cells was very similar to that in 037 and 041 cells; however, no enhancer activity was detected. It is conceivable that in 064 cells, the enhancer trap was initially integrated into a GAlcontaining locus, but the GAl was subsequently deleted during fixation of the foreign DNA sequence. As a result, the gpt gene was not linked to GA1, but nonetheless was expressed as highly as the GAl-linked gpt gene found in 037 and 041 cells. Although this finding may seem puzzling, a model consistent with this phenomenon is that GAl is by repeated freezing-thawing. CAT activity in the extracts was determined as described previously (12 cloned from 039 cells, the cloned 5'-flanking sequence was only 2 kb, and therefore it is possible that a gene activator is located further upstream. It is also possible that, as discussed for 064, the enhancer trap had been initially integrated near a gene activator which was subsequently deleted during cell division. Enhancer sequences can be artificially generated from the sequence of the enhancer trap itself, at the integration site in particular, as described in earlier reports (24, 27) . However, this is not the case for GAl and GA2. GA2 is located in human DNA sequences far from the integration site (Fig. 4) .
Furthermore, recent deletion mapping of GAl found that the deletion of 0.8 kb of DNA from the BamHI site (located approximately 3 kb downstream from the integration site; Fig. 4 (3) .
